Abstract
Cardiovascular disease (CVD) is a complex disease with multifactorial origin where cardiac membrane damage, inflammation, persistent oxidative stress, apoptosis and mitochondrial damage play a significant role. CVD is associated with high mortality rate and poor clinical outcome due to late diagnosis. Therefore, reliable accurate and specific biomarkers help in timely diagnosis and prevention of further damage. Beside creatine kinase-MB (CK-MB), cardiac troponin T (cTnT), brain natriuretic peptide (BNP), myeloperoxidase (MPO), etc. which are commonly used biomarkers, we need other supportive and accurate biomarkers for targeted diagnosis, as CVD is a complex diseased condition. Further, mechanism and symptoms of different types of CVD such as myocardial infarction, angina pectoris and heart failure are overlapping, hence in the recent time, multi-markers are used. Multi-markers include markers for oxidative stress, inflammation, apoptosis, membrane damage and energy metabolism. Understanding the etiology of disease, various novel markers have been developed and many of them are in pipeline. For bringing these biomarkers into clinical practice, various statistical criteria such as reclassification, discrimination and calibration are needed to validate and hence these novel biomarkers are yet to be used clinically. For pre-clinical studies, these markers play a vital role in establishing CVD and screening molecules for their cardio protective potential. We therefore, in the current manuscript have discussed various established and other important novel biomarkers for cardiovascular disorders, like biomarker for oxidative stress, cardiac inflammation, membrane damage, plaque rupture and thrombosis.
Keywords: Biomarkers, oxidative stress, inflammation, troponin, galactin-3, pentraxin-3, antigen carbohydrate-125.
Current Pharmaceutical Design
Title:Recent Updates on Current and Upcoming Biomarkers for Cardiovascular Diseases
Volume: 27 Issue: 37
Author(s): Ashif Iqubal, Aamir Khan, Adeeba laeeq, Kabil Malhotra, Mohd. A. Ansari and Syed E. Haque*
Affiliation:
- Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi-110062,India
Keywords: Biomarkers, oxidative stress, inflammation, troponin, galactin-3, pentraxin-3, antigen carbohydrate-125.
Abstract: Cardiovascular disease (CVD) is a complex disease with multifactorial origin where cardiac membrane damage, inflammation, persistent oxidative stress, apoptosis and mitochondrial damage play a significant role. CVD is associated with high mortality rate and poor clinical outcome due to late diagnosis. Therefore, reliable accurate and specific biomarkers help in timely diagnosis and prevention of further damage. Beside creatine kinase-MB (CK-MB), cardiac troponin T (cTnT), brain natriuretic peptide (BNP), myeloperoxidase (MPO), etc. which are commonly used biomarkers, we need other supportive and accurate biomarkers for targeted diagnosis, as CVD is a complex diseased condition. Further, mechanism and symptoms of different types of CVD such as myocardial infarction, angina pectoris and heart failure are overlapping, hence in the recent time, multi-markers are used. Multi-markers include markers for oxidative stress, inflammation, apoptosis, membrane damage and energy metabolism. Understanding the etiology of disease, various novel markers have been developed and many of them are in pipeline. For bringing these biomarkers into clinical practice, various statistical criteria such as reclassification, discrimination and calibration are needed to validate and hence these novel biomarkers are yet to be used clinically. For pre-clinical studies, these markers play a vital role in establishing CVD and screening molecules for their cardio protective potential. We therefore, in the current manuscript have discussed various established and other important novel biomarkers for cardiovascular disorders, like biomarker for oxidative stress, cardiac inflammation, membrane damage, plaque rupture and thrombosis.
Export Options
About this article
Cite this article as:
Iqubal Ashif , Khan Aamir , laeeq Adeeba , Malhotra Kabil , Ansari A. Mohd. and Haque E. Syed *, Recent Updates on Current and Upcoming Biomarkers for Cardiovascular Diseases, Current Pharmaceutical Design 2021; 27 (37) . https://dx.doi.org/10.2174/1381612827666210224143047
DOI https://dx.doi.org/10.2174/1381612827666210224143047 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Systematic Review on the Potential Applications of Theranostic
Nanoparticles in Diabetes and its Associated Complication Diabetic
Neuropathy
Current Nanomedicine Chemistry and Pharmacology of Bioactive Molecule -Coenzyme Q10: A Brief Note
Current Bioactive Compounds Chagas Disease Chemotherapy: What Do We Know So Far?
Current Pharmaceutical Design A Review of Stem Cell Therapy in Ischemic Heart Disease, Where are We Now?
New Emirates Medical Journal Role of Coronary Microvascular Endothelial Dysfunction in the Development of Heart Failure
Current Cardiology Reviews Effectiveness of Resveratrol Against Cardiovascular Disease
Mini-Reviews in Organic Chemistry Therapeutic Approaches Targeting Pathological Tau Aggregates
Current Pharmaceutical Design From Bone Marrow to Cardiac Atrial Appendage Stem Cells for Cardiac Repair: A Review
Current Medicinal Chemistry Enterovirus D-68 Molecular Virology, Epidemiology, and Treatment: an Update and Way Forward
Infectious Disorders - Drug Targets Emerging Role for Antioxidant Therapy in Protection Against Diabetic Cardiac Complications: Experimental and Clinical Evidence for Utilization of Classic and New Antioxidants
Current Cardiology Reviews Principles and Therapeutic Relevance for Targeting Mitochondria in Aging and Neurodegenerative Diseases
Current Pharmaceutical Design Why is the Inhibition of the Renin-Angiotensin System Effective for Preventing Cardiac Events in Patients with Coronary Risk Factors or Coronary Artery Disease?
Current Cardiology Reviews Safety and Efficacy of Adenovirus Carrying Hepatocyte Growth Factor Gene by Percutaneous Endocardial Injection for Treating Post-infarct Heart Failure: A Phase IIa Clinical Trial
Current Gene Therapy Gene Transfer for Inborn Errors of Metabolism of the Liver: The Clinical Perspective
Current Pharmaceutical Design An Overview of Published Papers and Important Developments in the Past Three Years
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Toll Like Receptors Signaling Pathways as a Target for Therapeutic Interventions
Current Signal Transduction Therapy Pharmacological Profile and Pharmacogenomics of Anti-Cancer Drugs Used for Targeted Therapy
Current Cancer Drug Targets Myocardial Expression of TNF-α, IL-1β, IL-6, IL-8, IL-10 and MCP-1 After a Single MDMA Dose Administered in a Rat Model
Current Pharmaceutical Biotechnology Natural Products to Anti-trypanosomal Drugs: An Overview of New Drug Prototypes for American Trypanosomiasis
Cardiovascular & Hematological Agents in Medicinal Chemistry RAGE: A Multi-Ligand Receptor Unveiling Novel Insights in Health and Disease
Current Medicinal Chemistry